Lower LDL confers fewer events in patients with CHD, diabete
Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...
Get authentic, real-time news that helps you fight COVID-19 better.
Install PlexusMD App for doctors. It's free.
Lower LDL levels were associated with fewer adverse events among patients with CHD and type 2 diabetes eligible for PCI or CABG, according to results published in the Journal of the American College of Cardiology.

Elevated low-density lipoprotein cholesterol (LDL-C) is associated with increased cardiovascular events, especially in high-risk populations.

This study sought to evaluate the influence of LDL-C on the incidence of cardiovascular events either following a coronary revascularization procedure (percutaneous coronary intervention [PCI] or coronary artery bypass grafting [CABG]) or optimal medical therapy alone in patients with established coronary heart disease and type 2 diabetes (T2DM).

Patient-level pooled analysis of 3 randomized clinical trials was undertaken. Patients with T2DM were categorized according to the levels of LDL-C at 1 year following randomization. The primary endpoint was major adverse cardiac or cerebrovascular events ([MACCE] the composite of all-cause mortality, nonfatal myocardial infarction, and nonfatal stroke).

-- A total of 4,050 patients were followed for a median of 3.9 years after the index 1-year assessment.

-- Patients whose 1-year LDL-C remained greater than 100 mg/dl experienced higher 4-year cumulative risk of MACCE (17.2% vs. 13.3% vs. 13.1% for LDL-C between 70 and less than 100 mg/dl and LDL-C leaa than 70 mg/dl, respectively).

-- When compared with optimal medical therapy alone, patients with PCI experienced a MACCE reduction only if 1-year LDL-C was less than 70 mg/dl, whereas CABG was associated with improved outcomes across all 1-year LDL-C strata.

-- In patients with 1-year LDL-C greater than 70 mg/dl, patients undergoing CABG had significantly lower MACCE rates as compared with PCI.

Conclusively, in patients with coronary heart disease with T2DM, lower LDL-C at 1 year is associated with improved long-term MACCE outcome in those eligible for either PCI or CABG. When compared with optimal medical therapy alone, PCI was associated with MACCE reductions only in those who achieved an LDL-C less than 70 mg/dl.

Source: https://www.jacc.org/doi/10.1016/j.jacc.2020.09.536